>유럽 줄기세포 치료 시장, 제품 유형별( 골수 유래 중간엽 세포, 태반 또는 탯줄 줄기세포, 지방 조직 유래 중간엽 줄기세포 및 기타), 유형(이종 줄기세포 치료 및 자가 줄기세포 치료), 응용 분야(근골격계 질환, 급성 이식편대숙주병(AGVHD), 상처 및 부상, 심혈관 질환, 수술, 위장 질환 및 기타), 최종 사용자(병원 및 수술 센터, 치료 회사, 서비스 회사 및 기타), 유통 채널(직접 입찰, 제3자 유통업체) 산업 동향 및 2029년까지의 예측
시장 분석 및 규모
암, 근골격계 질환 및 신경계 질환, 만성 부상, 심혈관 및 위장관 질환을 포함한 만성 질환은 입원, 장기 장애, 삶의 질 저하 및 사망으로 이어질 수 있습니다.
중간엽 줄기 세포는 여러 장기에 침투하여 통합되고, 심혈관, 폐, 척수 손상을 치료하고, 자가면역 질환, 간, 뼈 및 연골 질환의 상태를 개선합니다. 줄기 세포는 염증, 면역 체계 부전 및 조직 변성으로 인한 감염을 치료하는 강력한 도구입니다.
유럽 줄기세포 치료 시장 성장을 주도하는 요인은 만성 질환 발병률 증가, 세포 치료 생산 시설에 대한 GMP 인증 승인 증가, 생명공학 부문 성장, 줄기세포 기반 치료에 대한 임상 시험 증가입니다. 그러나 시장 성장을 억제할 것으로 예상되는 요인은 줄기세포 기반 연구 비용 증가, 줄기세포 치료를 받는 동안 직면하는 위험, 대안의 가용성입니다.
유럽 줄기세포 치료는 보조적이며 증상의 심각성을 줄이는 것을 목표로 합니다. Data Bridge Market Research는 유럽 줄기세포 치료 시장이 2022년에서 2029년까지의 예측 기간 동안 815만 달러의 가치에 도달하고 10.0%의 CAGR로 성장할 것으로 분석했습니다.
보고서 메트릭 |
세부 |
예측 기간 |
2022년부터 2029년까지 |
기준 연도 |
2021 |
역사적 해 |
2020 (2019-2014까지 사용자 정의 가능) |
양적 단위 |
수익 (단위: USD 백만) |
다루는 세그먼트 |
제품 유형별(골수 유래 중간엽 줄기 세포, 태반 또는 탯줄 줄기 세포, 지방 조직 유래 중간엽 줄기 세포 및 기타), 유형별(이종 줄기 세포 치료 및 자가 줄기 세포 치료), 적용 분야(근골격계 질환, 급성 이식편대숙주병(AGVHD), 상처 및 부상, 심혈관 질환, 수술, 위장 질환 및 기타), 최종 사용자(병원 및 수술 센터, 치료 회사, 서비스 회사 및 기타), 유통 채널(직접 입찰, 제3자 유통업체) |
적용 국가 |
이탈리아, 벨기에, 체코, 독일, 영국, 스페인, 헝가리, 폴란드 |
시장 참여자 포함 |
Takeda Pharmaceutical Company Limited, Holostem Terapie Avanzate S.r.l., JCR Pharmaceuticals Co., Ltd, ANTEROGEN.CO., LTD, MEDIPOST, Orthofix Medical Inc., BioRestorative Therapies, Inc., STEMPEUTICS RESEARCH PVT LTD, Pluristem Inc., among others |
Market Definition
Stem cells are the body's initial materials from which all other cells with specialized functions are generated. Under the right conditions in the body or a laboratory, stem cells divide to form more cells called daughter cells. The daughter cells become new stem cells or specialized cells (differentiation) with a more specific function, such as blood cells, brain cells, heart muscle cells, or bone cells. Much interest in stem cells has brought interest among the research scientists. Understanding how a disease develops and occurs by using stem cells, generating healthy cells to replace cells, and testing novel drug safety and efficacy are the scientific reasons why stem cell therapeutics are used.
Stem cell therapy promotes dysfunctional or injured tissue repair response using stem cells or derivatives. It is the next chapter in organ transplantation and uses cells instead of donor organs, which are limited in supply. The adult stem cells, such as adipose tissue-derived mesenchymal stem cells, bone marrow-derived mesenchymal stem cells, and placental or umbilical stem cells, are found in small numbers in most tissues. The embryonic stem cells originate from embryos, which are three to five days old. Emerging indications indicate that adult stem cells may be able to create various types of cells.
Europe Stem Cell Therapy Market Dynamics
Drivers
- Rise in prevalence and incidence of chronic diseases
Chronic diseases are common health conditions around the world. In Europe, one in three adults suffers from chronic conditions. Chronic diseases have affected the health and quality of life of many citizens. Chronic diseases—including cancer, musculoskeletal disorders and neurology disorders, chronic injuries, cardiovascular and gastrointestinal—can lead to hospitalization, long-term disability, reduced quality of life, and death.
The mesenchymal stem cells penetrate and integrate into multiple organs, repair cardiovascular, lung and spinal cord injuries, and improve the state of autoimmune diseases, liver, and bone and cartilage diseases. Stem cells are a potent tool for treating diseases caused by inflammation, immune system failure, and or tissue degeneration.
For instance,
- In 2021, according to the World Health Organization (WHO), approximately 1.7 billion people were down with musculoskeletal disorders worldwide. Low back pain causes a high burden of musculoskeletal disorders.
- Rise in research and development and availability of funding for stem cell research
The stem cell research is funded by the National Institute of Health (NIH) budget. The private sector also funds stem cell research, but such investment generally occurs later, during the testing and development phase, then during initial basic research. With stem cell therapies being such a new field, an unbiased governmental body must supervise them. The FDA is cautious and thorough, but they are endlessly struggling for funding, making a long-term investment that aligns the payment with the potential future beneficiaries.
For instance,
- In December 2021, in the U.K., the MRC and Biotechnology and BBSRC funded the U.K. Stem Cell Bank to carry out research projects for ethically approved, quality controlled, and assured repository of human embryonic, fetal and adult stem cell lines.
- Rise in GMP certification approvals for cell therapy production facilities
GMP ensures that products are consistently produced and controlled to state-of-the-art quality standards appropriate to their intended use. Thus, GMP principles significantly contribute to providing consumers and patients with products with consistent quality and high safety levels.
The GMP certification received would result in the prevention of errors. The accreditation received allows the manufacturers to produce cell lines in an identical, repeatable, sterile environment. Therefore, the GMP certification may boost the Europe stem cell therapy market growth.
Opportunities
- The rise in healthcare expenditure
Moreover, the rise in the research and development activities and increasing investments by government and private organization will boost new opportunities for the market's growth rate.
For instance,
- In 2020, according to Eurostat, the health expenditure in the European Union amounted to USD 1,309.6 million
- Strategic initiatives by market players
The demand for stem cell therapy has increased the demand in Europe owing to the timely treatment of chronic conditions. These favorable factors enhance the need for medications, and to achieve the market demand, minor and major market players are utilizing various strategies.
The major players are also trying to devise specific strategies, such as product launches, acquisitions, approvals, expansions, and partnerships, to ensure the smooth running of the business, avoid risks, and increase the long-term growth in the sales of the market.
These strategic initiatives by the market players, including acquisition, conferences, and focused segment product launches, are helping the companies grow and improve the company's product portfolios, ultimately leading to more revenue generation. Hence, these strategic initiatives by the market players provide an opportunity that is helping them to drive market growth.
Restraints/Challenges
- The rise in cost of stem-cell based therapy research
Stem cell therapy is a developing and novel treatment option for treating several disorders. Sometimes, the cost of the therapy is a concern for several conditions. The stem-cell therapy treatment procedures. The stem cell field is still highly specialized and has not been adopted by the mainstream and insurance companies. The cost of stem cell therapy-based research therapy is not covered by medical insurance. These costs are pushed on patients. Therefore, the present high cost is expected to show a descending trend.
For instance,
- In 2021, the data by Gift of Life, a U.K. sister charity to Podari Zhizn, stated that the cost of stem cell therapy for musculoskeletal disorders is USD 4861.44 to USD 5401.60
- The risks faced while undergoing stem cell therapy
Specific risks are observed by stem cell therapists and research scientists while developing the stem cell therapeutic models. The main challenge faced while using stem cell therapy is optimal cell sourcing. Stem cell therapy is well established and rapidly growing in developed countries; however, certain risks shield the growth of this therapy in developing countries. The criteria limit the use of stem cell therapy. Hence, there are certain risks observed for patients undergoing stem cell therapy.
For instance,
- The risks faced while undergoing stem cell therapy are genetic instability, tumor formation, inappropriate stem cell formation, immune rejection of transplanted stem cells, hemorrhage during neurosurgery, and postoperative infection
- The risks faced after stem cell transplantation is improper distribution and localization of stem cell after transplant. Pluripotent stem cells can form teratoma (tumor)
- Stringent regulations
The regulatory guidelines for stem cell therapeutics are strict compared to older ones. The manufacturers have to make specific product changes before approval, which is expected to cause delays. The companies have to carefully review the product specifications and certifications before categorizing their product according to the Food and Drug Administration (FDA) and the European Union (E.U.). Every country has its regulatory authority responsible for enforcing rules and regulations for drug development, licensing, registration, manufacturing, marketing, and labeling of pharmaceutical products.
FDA's Center for Biologics Evaluation & Research (CBER) regulates human tissues, cells, and tissue-based products intended for transplantation, including hematopoietic stem cells.
For instance,
- In the U.K., the Medicines and Healthcare Products Regulatory Agency (MHRA) regulates and provides guidelines for stem cell therapy; when stem cell therapy is considered to be a Medicinal Product (M.P.), for quality and safety (Q and S), testing regulations
The Europe stem cell therapy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on t Europe stem cell therapy market, contact Data Bridge Market Research for an Analyst Brief; our team will help you make an informed market decision to achieve market growth.
Patient Epidemiology Analysis
The Europe stem cell therapy market also provides you with detailed market analysis for patient analysis, prognosis, and cures. Prevalence, incidence, mortality, and adherence rates are some of the data variables available in the report. Direct or indirect impact analyses of epidemiology to the market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market during the growth period.
Impact of COVID-19 on the Europe Stem Cell Therapy Market
During the pandemic, stem cell therapy had a remarkable effect on reducing mortality and morbidity of patients with COVID-19. Further large-scale studies are needed to approve these results. A protocol for stem cell therapy in COVID-19 infection should be defined to achieve the best possible clinical outcomes. Clinical trials were conducted during COVID-19.
Recent Development
- In September 2020, Takeda Pharmaceutical Company Limited. had received product approval from the Japan Ministry of Health, Labour and Welfare to manufacture and market Alofisel (darvadstrocel) and adipose-derived mesenchymal stem cells for the treatment of complex perianal fistulas in patients with non-active or mildly active luminal Crohn's disease (CD). The approval received would result in post-market approval and product launch. This is expected to increase the market growth.
Europe Stem Cell Therapy Market Scope
The Europe stem cell therapy market is segmented into five segments based on product type, type, application, end user, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product Type
- Bone Marrow Derived Mesenchymal Stem Cells
- Placental or Umbilical Stem Cell
- Adipose Tissue Derived Mesenchymal Stem Cells
- Others
유럽 줄기세포 치료 시장은 제품 유형을 기준으로 골수 유래 중간엽 줄기세포, 태반 또는 태아줄기세포, 지방 조직 유래 중간엽 줄기세포 및 기타로 구분 됩니다 .
유형
- 동종 줄기 세포 치료
- 자가줄기세포 치료
유럽 줄기세포 치료 시장은 유형을 기준으로 동종줄기세포 치료와 자가줄기세포 치료로 구분됩니다.
애플리케이션
- 근골격계 질환
- 상처와 부상
- 급성 이식편대숙주병(AGVHD)
- 수술
- 위장관 질환
- 심혈관 질환
- 기타
유럽 줄기세포 치료 시장은 응용 분야별로 근골격계 질환, 상처 및 부상, 급성 이식편대숙주병(AGVHD), 수술, 위장관 질환 , 심혈관 질환 및 기타로 구분됩니다.
최종 사용자
- 병원 및 수술 센터
- 치료 회사
- 서비스 회사
- 기타
유럽 줄기세포 치료 시장은 최종 사용자를 기준으로 병원 및 수술 센터, 치료 회사, 서비스 회사 및 기타로 구분됩니다.
유통 채널
- 직접 입찰
- 제3자 유통업체
유럽 줄기세포 치료 시장은 유통 채널을 기준으로 직접 입찰과 제3자 유통업체로 구분됩니다.
유럽 줄기세포 치료 시장 지역 분석/통찰력
위에 언급된 대로 유럽 줄기세포 치료 시장을 분석하고, 지역, 제품 유형, 응용 분야, 최종 사용자 및 유통 채널별로 시장 규모에 대한 통찰력과 추세를 제공합니다.
유럽 줄기세포 치료 시장 보고서에 포함된 국가로는 이탈리아, 벨기에, 체코, 독일, 영국, 스페인, 헝가리, 폴란드가 있습니다. 이탈리아는 인간 줄기세포 분야의 줄기세포 연구 및 개발에 대한 임상 시험 승인이 증가함에 따라 시장을 지배할 것으로 예상됩니다.
보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변경 사항을 제공합니다. 신규 판매, 교체 판매, 국가 인구 통계, 질병 역학 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 유럽 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 판매 채널의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.
경쟁 환경 및 유럽 줄기세포 치료 시장 점유율 분석
유럽 줄기세포 치료 시장 경쟁 구도는 경쟁자에 대한 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 유럽의 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭 및 범위, 응용 분야 우세입니다. 위에 제공된 데이터 포인트는 유럽 줄기세포 치료 시장과 관련된 회사의 초점에만 관련이 있습니다.
유럽 줄기세포 치료 시장의 주요 기업으로는 Takeda Pharmaceutical Company Limited, Holostem Terapie Avanzate Srl, JCR Pharmaceuticals Co., Ltd, ANTEROGEN.CO., LTD, MEDIPOST, Orthofix Medical Inc., BioRestorative Therapies, Inc., STEMPEUTICS RESEARCH PVT LTD, Pluristem Inc. 등이 있습니다.
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석 및 추정됩니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용을 알아보려면 분석가 전화를 요청하거나 문의 사항을 드롭 다운하세요. DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 기본(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 이 외에도 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 회사 시장 점유율 분석, 측정 표준, 유럽 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의 사항을 드롭하여 산업 전문가에게 문의하세요.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE STEM CELL THERAPY MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 EUROPE STEM CELL THERAPY MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT SEGMENT LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET END USER COVERAGE GRID
2.11 SECONDARY SOURCES
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL
4.2 PORTER'S FIVE FORCES MODEL
5 EPIDEMIOLOGY
6 PIPELINE ANALYSIS FOR THE EUROPE STEM CELL THERAPY MARKET
7 EUROPE STEM CELL THERAPY MARKET: REGULATIONS
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 THE RISE IN PREVALENCE AND INCIDENCE OF CHRONIC DISEASES
8.1.2 RISE IN INVESTMENT IN RESEARCH AND DEVELOPMENT AND AVAILABILITY OF FUNDING FOR STEM CELL RESEARCH
8.1.3 GROWING BIOTECHNOLOGY SECTOR
8.1.4 RISE IN GMP CERTIFICATION APPROVALS FOR CELL THERAPY PRODUCTION FACILITIES
8.1.5 RISE IN CLINICAL TRIALS FOR STEM-CELL-BASED THERAPIES
8.2 RESTRAINTS
8.2.1 THE RISE IN COST OF STEM-CELL-BASED THERAPY RESEARCH
8.2.2 THE RISKS FACED WHILE UNDERGOING STEM CELL THERAPY
8.2.3 ETHICAL CONCERNS RELATED TO STEM CELL THERAPY RESEARCH
8.2.4 AVAILABILITY OF ALTERNATIVES
8.3 OPPORTUNITIES
8.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS
8.3.2 RISE IN HEALTHCARE EXPENDITURE
8.3.3 THE EMERGENCE OF INDUCED PLURIPOTENT STEM CELLS (IPSCS)
8.4 CHALLENGES
8.4.1 THE LACK OF SKILLED PROFESSIONALS REQUIRED FOR STEM CELL THERAPY
8.4.2 STRINGENT REGULATIONS
9 EUROPE STEM CELL THERAPY MARKET, BY PRODUCT TYPE
9.1 OVERVIEW
9.2 BONE MARROW DERIVED MESENCHYMAL STEM CELLS
9.3 PLACENTAL/UMBILICAL STEM CELL
9.4 ADIPOSE TISSUE DERIVED MESENCHYMAL STEM CELLS
9.5 OTHERS
10 EUROPE STEM CELL THERAPY MARKET, BY TYPE
10.1 OVERVIEW
10.2 ALLOGENEIC STEM CELL THERAPY
10.2.1 MUSCULOSKELETAL DISORDERS
10.2.2 WOUNDS AND INJURIES
10.2.3 ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
10.2.4 SURGERIES
10.2.5 GASTROINTESTINAL DISEASES
10.2.6 OTHER APPLICATION
10.3 AUTOLOGOUS STEM CELL THERAPY
10.3.1 CARDIOVASCULAR DISEASES
10.3.2 GASTROINTESTINAL DISEASES
10.3.3 OTHER APPLICATION
11 EUROPE STEM CELL THERAPY MARKET, BY APPLICATION
11.1 OVERVIEW
11.2 MUSCULOSKELETAL DISORDERS
11.3 WOUNDS AND INJURIES
11.4 ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)
11.5 SURGERIES
11.6 GASTROINTESTINAL DISEASES
11.7 CARDIOVASCULAR DISEASES
11.8 OTHER APPLICATION
12 EUROPE STEM CELL THERAPY MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITAL AND SURGICAL CENTERS
12.3 THERAPEUTIC COMPANIES
12.4 SERVICES COMPANIES
12.5 OTHERS
13 EUROPE STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 THIRD PARTY DISTRIBUTORS
14 EUROPE STEM CELL THERAPY MARKET, BY REGION
14.1 EUROPE
14.1.1 ITALY
14.1.2 BELGIUM
14.1.3 CZECH REPUBLIC
14.1.4 GERMANY
14.1.5 U.K.
14.1.6 SPAIN
14.1.7 HUNGARY
14.1.8 POLAND
15 EUROPE STEM CELL THERAPY MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: EUROPE
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 OSIRIS THERAPEUTICS, INC. (A SUBSIDIARY OF SMITH+NEPHEW) (2021)
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENT
17.2 JCR PHARMACEUTICALS CO., LTD ( (2021)
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENTS
17.3 ORTHOFIX MEDICAL INC. (2021)
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENTS
17.4 MEDIPOST (2021)
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENTS
17.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED (2021)
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENT
17.6 CORESTEM, INC. (2021)
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENT
17.7 PHARMICELL CO., LTD. (2021)
17.7.1 COMPANY SNAPSHOT
17.7.2 PRODUCT PORTFOLIO
17.7.3 RECENT DEVELOPMENTS
17.8 ANTEROGEN.CO., LTD (2021)
17.8.1 COMPANY SNAPSHOT
17.8.2 PRODUCT PORTFOLIO
17.8.3 RECENT DEVELOPMENTS
17.9 ATHERSYS, INC.(2021)
17.9.1 COMPANY SNAPSHOT
17.9.2 REVENUE ANALYSIS
17.9.3 PRODUCT PORTFOLIO
17.9.4 RECENT DEVELOPMENTS
17.1 BRAINSTORM CELL LIMITED (2021)
17.10.1 COMPANY SNAPSHOT
17.10.2 PRODUCT PORTFOLIO
17.10.3 RECENT DEVELOPMENTS
17.11 BIORESTORATIVE THERAPIES, INC. (2021)
17.11.1 COMPANY SNAPSHOT
17.11.2 REVENUE ANALYSIS
17.11.3 PRODUCT PORTFOLIO
17.11.4 RECENT DEVELOPMENTS
17.12 HOLOSTEM TERAPIE AVANZATE S.R.L. (2021)
17.12.1 COMPANY SNAPSHOT
17.12.2 PRODUCT PORTFOLIO
17.12.3 RECENT DEVELOPMENTS
17.13 INTERNATIONAL STEMCELL CORPORATION (2021)
17.13.1 COMPANY SNAPSHOT
17.13.2 REVENUE ANALYSIS
17.13.3 PRODUCT PORTFOLIO
17.13.4 RECENT DEVELOPMENT
17.14 MESOBLAST LTD (2021)
17.14.1 COMPANY SNAPSHOT
17.14.2 REVENUE ANALYSIS
17.14.3 PRODUCT PORTFOLIO
17.14.4 RECENT DEVELOPMENTS
17.15 PLURISTEM INC.(2021)
17.15.1 COMPANY SNAPSHOT
17.15.2 REVENUE ANALYSIS
17.15.3 PRODUCT PORTFOLIO
17.15.4 RECENT DEVELOPMENT
17.16 STEMPEUTICS RESEARCH PVT LTD
17.16.1 COMPANY SNAPSHOT
17.16.2 PRODUCT PORTFOLIO
17.16.3 RECENT DEVELOPMENTS
17.17 U.S. STEM CELL, INC. (2021)
17.17.1 COMPANY SNAPSHOT
17.17.2 REVENUE ANALYSIS
17.17.3 PRODUCT PORTFOLIO
17.17.4 RECENT DEVELOPMENT
18 QUESTIONNAIRE
19 RELATED REPORTS
표 목록
TABLE 1 EUROPE STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 2 EUROPE BONE MARROW DERIVED MESENCHYMAL STEM CELLS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 EUROPE PLACENTAL/UMBILICAL STEM CELL IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 EUROPE ADIPOSE TISSUE DERIVED MESENCHYMAL STEM CELLS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 EUROPE OTHERS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 EUROPE STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 7 EUROPE ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 EUROPE ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 9 EUROPE AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 EUROPE AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 11 EUROPE STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 12 EUROPE MUSCULOSKELETAL DISORDERS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 EUROPE WOUNDS AND INJURIES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 EUROPE ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 15 EUROPE SURGERIES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 EUROPE GASTROINTESTINAL DISEASES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 EUROPE CARDIOVASCULAR DISEASES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 EUROPE OTHER APPLICATION IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 EUROPE STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 20 EUROPE HOSPITAL AND SURGICAL CENTERS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 EUROPE THERAPEUTIC COMPANIES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 EUROPE SERVICES COMPANIES IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 EUROPE OTHERS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 EUROPE STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 25 EUROPE DIRECT TENDER IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 EUROPE THIRD PARTY DISTRIBUTORS IN STEM CELL THERAPY MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 EUROPE STEM CELL THERAPY MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 28 EUROPE STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 29 EUROPE STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 30 EUROPE ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 31 EUROPE AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 32 EUROPE STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION)
TABLE 33 EUROPE STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 34 EUROPE STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 35 ITALY STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 36 ITALY STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 37 ITALY ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 38 ITALY AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 39 ITALY STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION)
TABLE 40 ITALY STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 41 ITALY STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 42 BELGIUM STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 43 BELGIUM STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 44 BELGIUM ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 45 BELGIUM AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 46 BELGIUM STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION)
TABLE 47 BELGIUM STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 48 BELGIUM STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 49 CZECH REPUBLIC STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 50 CZECH REPUBLIC STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 51 CZECH REPUBLIC ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 52 CZECH REPUBLIC AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 53 CZECH REPUBLIC STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION)
TABLE 54 CZECH REPUBLIC STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 55 CZECH REPUBLIC STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 56 GERMANY STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 57 GERMANY STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 58 GERMANY ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 59 GERMANY AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 60 GERMANY STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION)
TABLE 61 GERMANY STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 62 GERMANY STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 63 U.K. STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 64 U.K. STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 65 U.K. ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 66 U.K. AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 67 U.K. STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION)
TABLE 68 U.K. STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 69 U.K. STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 70 SPAIN STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 71 SPAIN STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 72 SPAIN ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 73 SPAIN AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 74 SPAIN STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION)
TABLE 75 SPAIN STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 76 SPAIN STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 77 HUNGARY STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 78 HUNGARY STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 79 HUNGARY ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 80 HUNGARY AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 81 HUNGARY STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION)
TABLE 82 HUNGARY STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 83 HUNGARY STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 84 POLAND STEM CELL THERAPY MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 85 POLAND STEM CELL THERAPY MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 86 POLAND ALLOGENEIC STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 87 POLAND AUTOLOGOUS STEM CELL THERAPY IN STEM CELL THERAPY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 88 POLAND STEM CELL THERAPY MARKET, BY APPLICATIONS, 2020-2029 (USD MILLION)
TABLE 89 POLAND STEM CELL THERAPY MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 90 POLAND STEM CELL THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
그림 목록
FIGURE 1 EUROPE STEM CELL THERAPY MARKET : SEGMENTATION
FIGURE 2 EUROPE STEM CELL THERAPY MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE STEM CELL THERAPY MARKET: DROC ANALYSIS
FIGURE 4 EUROPE STEM CELL THERAPY MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE STEM CELL THERAPY MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE STEM CELL THERAPY MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE STEM CELL THERAPY MARKET: DBMR POSITION GRID
FIGURE 8 EUROPE STEM CELL THERAPY MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 EUROPE STEM CELL THERAPY MARKET: END USER COVERAGE GRID
FIGURE 10 EUROPE STEM CELL THERAPY MARKET: SEGMENTATION
FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE EUROPE STEM CELL THERAPY MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 INCREASED INCIDENCE OF CHRONIC DISEASES, RISE IN CLINICAL TRIALS, GMP CERTIFICATION AND PRODUCT APPPROVALS IS EXPECTED TO DRIVE THE EUROPE STEM CELL THERAPY MARKET FROM 2022 TO 2029
FIGURE 13 PRODUCT TYPE SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE EUROPE STEM CELL THERAPY MARKET FROM 2022 & 2029
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE STEM CELL THERAPY MARKET
FIGURE 15 NUMBER AND AGES OF PEOPLE 65 OR OLDER WITH ALZHEIMER'S DEMENTIA IN 2022
FIGURE 16 INCIDENCE OF VARIOUS TYPES OF CANCER IN 2020
FIGURE 17 EUROPE STEM CELL THERAPY MARKET: BY PRODUCT TYPE, 2021
FIGURE 18 EUROPE STEM CELL THERAPY MARKET: BY PRODUCT TYPE, 2022-2029 (USD MILLION)
FIGURE 19 EUROPE STEM CELL THERAPY MARKET: BY PRODUCT TYPE, CAGR (2022-2029)
FIGURE 20 EUROPE STEM CELL THERAPY MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 21 EUROPE STEM CELL THERAPY MARKET: BY TYPE, 2021
FIGURE 22 EUROPE STEM CELL THERAPY MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 23 EUROPE STEM CELL THERAPY MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 24 EUROPE STEM CELL THERAPY MARKET: BY TYPE, LIFELINE CURVE
FIGURE 25 EUROPE STEM CELL THERAPY MARKET: BY APPLICATION, 2021
FIGURE 26 EUROPE STEM CELL THERAPY MARKET: BY APPLICATION, 2022-2029 (USD MILLION)
FIGURE 27 EUROPE STEM CELL THERAPY MARKET: BY APPLICATION, CAGR (2022-2029)
FIGURE 28 EUROPE STEM CELL THERAPY MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 29 EUROPE STEM CELL THERAPY MARKET: BY END USER, 2021
FIGURE 30 EUROPE STEM CELL THERAPY MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 31 EUROPE STEM CELL THERAPY MARKET: BY END USER, CAGR (2022-2029)
FIGURE 32 EUROPE STEM CELL THERAPY MARKET: BY END USER, LIFELINE CURVE
FIGURE 33 EUROPE STEM CELL THERAPY MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 34 EUROPE STEM CELL THERAPY MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 35 EUROPE STEM CELL THERAPY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 36 EUROPE STEM CELL THERAPY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 37 EUROPE STEM CELL THERAPY MARKET: SNAPSHOT (2021)
FIGURE 38 EUROPE STEM CELL THERAPY MARKET: BY COUNTRY (2021)
FIGURE 39 EUROPE STEM CELL THERAPY MARKET: BY COUNTRY (2022 & 2029)
FIGURE 40 EUROPE STEM CELL THERAPY MARKET: BY COUNTRY (2021 & 2029)
FIGURE 41 EUROPE STEM CELL THERAPY MARKET: BY PRODUCT TYPE (2022 & 2029)
FIGURE 42 EUROPE STEM CELL THERAPY MARKET: COMPANY SHARE 2021 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.